Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.
Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N.
Cancer Sci. 2021 Jul;112(7):2607-2624. doi: 10.1111/cas.14933. Epub 2021 Jun 11.
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, Mounier N, Gisselbrecht C, Faure P, Thieblemont C.
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):262-9. doi: 10.3816/CLML.2010.n.055.
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
Trkulja KL, Manji F, Kuruvilla J, Laister RC.
Biomolecules. 2023 Jan 5;13(1):111. doi: 10.3390/biom13010111.
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.
J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.
The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis.
Hu L, Luo D, Zhou T, Tao Y, Feng J, Mei S.
Environ Pollut. 2017 Dec;231(Pt 1):319-328. doi: 10.1016/j.envpol.2017.08.028. Epub 2017 Aug 12.
Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Sana T, Qayyum S, Jabeen A, Siddiqui BS, Begum S, Siddiqui RA, Hadda TB.
J Ethnopharmacol. 2022 Jul 15;293:115267. doi: 10.1016/j.jep.2022.115267. Epub 2022 Apr 7.
PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL, Brown JR.
Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6.
XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?
Burkhardt B, Lenz G.
Hematol Oncol. 2015 Jun;33 Suppl 1:62-6. doi: 10.1002/hon.2219.
Non-Hodgkin lymphoma and pesticide exposure in Turkey.
Yildirim M, Karakilinc H, Yildiz M, Kurtoglu E, Dilli UD, Goktas S, Demirpence O, Kaya V.
Asian Pac J Cancer Prev. 2013;14(6):3461-3. doi: 10.7314/apjcp.2013.14.6.3461.
